IL6 and scleroderma: 2011). It is increased in patients with scleroderma and significantly correlates with the disease severity scoring system (Shima et al. 2010). Substantial evidence has been gathered to support the role of IL-6 in the disease activity and the development of cardiopulmonary manifestations in patients with SSc (Distler et al. 2020).